Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following ...

In the assessment of 12-month price targets, analysts unveil insights for Sangamo Therapeutics, presenting an average target ...

Sangamo (SGMO) delivered earnings and revenue surprises of -22.22% and 52.51%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The company said, “2025 operating expenses on a non-GAAP basis are expected to be roughly in line with 2024, reflecting our intention to ...

Pre-earnings options volume in Sangamo (SGMO) is normal with calls leading puts 15:1. Implied volatility suggests the market is anticipating a ...

The average 12 month price objective among brokers that have issued a report on the stock in the last year is $5.80. Several equities research analysts have recently weighed in on SGMO shares.

Sangamo posted a Q4 loss of $0.11 per share, $0.01 worse than the $0.10 loss analysts had forecast. Revenue for the quarter came in at $7.55 million, missing the consensus estimate of $10.32 million.

Today, several major companies are expected to report earnings: CBAK Energy Technology (CBAT), Sangamo Biosciences (SGMO), ...

Sangamo Therapeutics Inc. SGMO) on Monday reported a loss of $23.4 million in its fourth quarter.

SANGAMO THERAPEUTICS ($SGMO) is expected to release its quarterly earnings data on Monday, March 17th after market close, per Finnhub. Analysts are expecting revenue ...

The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $5.17. A number of analysts have recently weighed in on SGMO shares. Barclays upped ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...